Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Size: px
Start display at page:

Download "Medical Policy An independent licensee of the Blue Cross Blue Shield Association"

Transcription

1 Self Administered Oncology Agents Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior Authorization requests. Prior Authorization Form: Link to Drug List (Formulary): Professional Institutional Original Effective Date: January 1, 2011 Original Effective Date: January 1, 2011 Revision Date(s): February 1, 2012; Revision Date(s): February 1, 2012; July 1, 2012; March 1, 2013; July 1, 2012; March 1, 2013; September 1, 2013; February 28, 2014; September 1, 2013; February 28, 2014; August 28, 2014; October 1, 2014; August 28, 2014; October 1, 2014; October 1, 2015; January 1, 2016; October 1, 2015; January 1, 2016; February 24, 2016, April 1, 2016; July 1, 2016; February 24, 2016, April 1, 2016; July 1, 2016; November 1, 2016; February 1, 2017; November 1, 2016; February 1, 2017; April 1, 2017, May 1, 2017; July 1, 2017; April 1, 2017; May 1, 2017; July 1, 2017; July 15, 2017; October 1, 2017; July 15, 2017; October 1, 2017; November 1, 2017; November 27, 2017; November 1, 2017; November 27, 2017; December 11, 2017; January 1, 2018; December 11, 2017; January 1, 2018; February 5, 2018; March 12, 2018; February 5, 2018; March 12, 2018; March 26, 2018; April 23, 2018; June 25, 2018; March 26, 2018; April 23, 2018; June 25, 2018; July 23, 2018 July 23, 2018 Current Effective Date: July 23, 2018 Current Effective Date: July 23, 2018 State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service. The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health isurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice. If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

2 Self Administered Oncology Agents Page 2 of 19 DESCRIPTION The intent of the Self Administered Oncology Agents Prior Authorization (PA) program is to ensure appropriate selection of patients for treatment according to product labeling and/or clinical studies and/or clinical guidelines. The criteria considers appropriate indications as those supported in FDA approved labeling, National Comprehensive Cancer Network (NCCN) with level of evidence of 1 or 2A recommendation, AHFS, or Drugdex with level of evidence of 1 or IIa. If there are preferred agents, as determined by the client, the criteria will require use of the preferred agent before the non-preferred agent. Target Drugs Afinitor (everolimus) Afinitor Disperz (everolimus) Alecensa (alectinib) Alunbrig (brigatinib) Bosulif (bosutinib) Braftovi (encorafenib) Cabometyx (cabozantinib) Calquence (acalabrutinib) Caprelsa (vandetanib) Cometriq (cabozantinib) Cotellic TM (cobimetinib) Erleada (apalutamide) Erivedge (vismodegib) Farydak (panobinostat) Gilotrif (afatinib) Gleevec (imatinib) a Hexalen (altretamine) Hycamtin (topotecan) Ibrance (palbociclib) Iclusig (ponatinib) Idhifa (enasibenib) Imbruvica (ibrutinib) Inlyta (axitinib) Iressa (gefitinib) Jakafi (ruxolitinib) Kisqali (ribociclib) Kisqali Femara Pack (ribociclib and letrozole co-packaged) Lenvima (lenvatinib) Lonsurf (trifluridine/tipiracil) Lynparza (olaparib) capsules Lynparza (olaparib) tablets Lysodren (mitotane) Matulane (procarbazine) Mekinist (trametinib) a generic available Mektovi (binimetinib) Nerlynx (neratinib) Nexavar (sorafenib) Ninlaro (ixazomib) Odomzo (sonidegib) Pomalyst (pomalidomide) Revlimid (lenalidomide) Rubraca TM (rucaparib) Rydapt (midostaurin) Sprycel (dasatinib) Stivarga (regorafenib) Sutent (sunitinib) Sylatron (peginterferon alfa-2b) Tafinlar (dabrafenib) Tagrisso TM (osimertinib) Tarceva (erlotinib) Targretin (bexarotene) a Tasigna (nilotinib) Temodar (temozolomide) a Thalomid (thalidomide) Tretinoin (oral) Tykerb (lapatinib) Venclexta TM (venetoclax) Verzenio (abemaciclib) Votrient (pazopanib) Xalkori (crizotinib) Xeloda (capecitabine) a Xtandi (enzalutamide) Yonsa (abiraterone acetate) Zejula (niraparib) Zelboraf (vemurafenib) Zolinza (vorinostat) Zydelig (idelalisib) Zykadia TM (ceritinib) Zytiga (abiraterone)

3 Self Administered Oncology Agents Page 3 of 19 FDA Approved Indications 1-51, Medication Indication Dosing Afinitor (everolimus) Afinitor Disperz (everolimus) Alecensa (alectinib) Alunbrig (brigatinib) Bosulif (bosutinib) Braftovi (encorafenib) Cabometyx tablets (cabozantinib) Calquence (acalabrutinib) Caprelsa (vandetanib) Cometriq capsules (cabozantinib) Cotellic (cobimetinib) Erleada (apalutamide) Advanced HR+BC* RCC* Renal Angiomyolipoma with TSC SEGA with TSC PNET NET of GI or lung origin ø SEGA with TSC in pediatrics and adults ALK positive metastatic NSCLC * ALK positive NSCLC* CML chronic, accelerated or blast phase Ph+* In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDAapproved test RCC MCL* Locally advanced or metastatic MTC MTC Unresectable or metastatic melanoma with BRAF V600E or V600K mutation Treatment of patients with non-metastatic castrationresistant prostate cancer Advanced HR+BC, PNET, NET, RCC, renal angiomyolipoma with TSC: 10 mg once daily ^SEGA and TSC: 4.5 mg/m 2 once daily, adjusted to attain trough concentrations of 5-15 ng/ml ^Administration with strong CYP3A4 inducer requires dose of 9 mg/m mg/m 2 once daily, adjusted to attain trough concentrations of 5-15 ng/ml. Administration with strong CYP3A4 inducer requires dose of 9 mg/m 2. Metastatic NSCLC: 600 mg orally twice daily NSCLC: 90 mg orally once daily for the first 7 days; if tolerated, increase to 180 mg orally once daily CML ± : 500 mg orally once daily until disease progression. Consider increasing to 600 mg daily for incomplete response. ± Adjusted dosing: Renal impairment: 300 mg 400 mg daily based on CrCl Mild, moderate, severe and hepatic impairment- 200 mg daily Melanoma: 450 mg orally once daily in combination with binimetinib until disease progression or unacceptable toxicity. If adverse reactions are unacceptable, reduce dose to 300 mg once daily. If further dose reduction is required, reduce dose to 200 mg daily. Permanently discontinue if unable to tolerate Braftovi 200 mg once daily. RCC: 60 mg orally once daily. Do NOT substitute Cabometyx tablets with Cometriq (cabozantinib) capsules MCL: 100 mg every 12 hours MTC: 300 mg once daily. Start at 200 mg daily for patients with several renal impairment. MTC: 140 mg orally once daily Do NOT substitute Cometriq (cabozantinib) capsules with Cabometyx (cabozantinib) tablets Melanoma: 60 mg orally once daily for 21 days of each 28 day cycle Non-metastatic castration resistant prostate cancer: 240 mg once daily Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy

4 Self Administered Oncology Agents Page 4 of 19 Medication Indication Dosing Erivedge BCC BCC: 150 mg orally once daily (vismodegib) Farydak MM** MM: Treatment phase I: Cycles 1-8, 3 week cycles (total (panobinostat) time 24 weeks): Panobinostat 20 mg orally once every other day for 3 doses per week in weeks 1 and 2 of each 21-day cycle for up to 8 cycles (see label for combination use with bortezomib and dexamethasone) An additional 8 cycles can be considered in those with clinical benefit Gilotrif (afatinib) Gleevec a (imatinib) Hexalen (altretamine) Hycamtin (topotecan) Ibrance (palbociclib) Iclusig (ponatinib) Idhifa (enasidenib) NSCLC, first line for EGFR substitution mutations GT Progressed metastatic, squamous NSCLC* Ph+ CML Ph+ CML blast crisis, accelerated phase, chronic phase* Ph+ ALL, Ph+ pediatric ALL MDS/MPD ASM HES CEL DFSP GIST NSCLC: 40 mg orally once daily Ph+ CML: 400 mg/day in chronic phase; 600 mg/day in accelerated phase or blast crisis; pediatrics 340 mg/m 2 /day in chronic phase (not to exceed 600 mg) ALL: 600 mg/day; pediatrics 340 mg/m 2 /day (not to exceed 600 mg) MDS/MPD: 400mg/day GIST: 400 mg/day (not to exceed 800 mg/day) ASM, HES/CEL: mg/day DFSP: 800 mg/day OC* OC: 260 mg/m 2 /day in 4 divided doses for 14 or 21 consecutive days in a 28 day cycle SCLC* SCLC: 2.3mg/m 2 /day for 5 days, repeated every 21 days Advanced/metastatic ER+ HER2 negative BC in Postmenopausal women ~ Women with disease progression following endocrine therapy CML, Ph+ ALL T315I + CML T315I +,Ph + ALL Relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation GT BC: 125 mg daily for 21 days followed by 7 days off treatment CML & Ph+ ALL, T315I + CML, T315I +,Ph + ALL: 45 mg orally one daily until disease progression. AML: 100 mg orally once daily

5 Self Administered Oncology Agents Page 5 of 19 Medication Indication Dosing MCL* CLL/SLL CLL/SLL with 17p deletion Waldenströms macroglobulinemia (WM) Marginal zone lymphoma (MZL)* Chronic GVHD after failure of one or more lines of systemic therapy Imbruvica (ibrutinib) Inlyta (axitinib) Iressa (gefitinib) Jakafi (ruxolitinib) Kisqali (ribociclib) Kisqali Femara Pack (ribociclib and letrozole co-packaged) Lenvima (lenvatinib) Lonsurf (trifluridine/tipiracil) Lynparza (olaparib) capsules RCC* NSCLC, first line for EGFR deletion of exon 19 or exon 21 (L858R) substitution mutations GT Myelofibrosis Polycythemia vera^ HR-positive, HER2 negative advanced or metastatic BC in postmenopausal women HR-positive, HER2 negative advanced or metastatic BC in postmenopausal women DTC RCC MCL, MZL: 560 mg orally once daily. CLL/SLL, WM, and Chronic GVHD: 420 mg orally once daily. RCC: 5 mg orally twice daily. Max dose 10 mg twice daily NSCLC: 250 mg orally once daily Myelofibrosis: 5-20 mg orally twice daily depending on platelet count. Max dose is 25 mg twice daily. Polycythemia vera (PV): 10 mg orally twice daily BC: 600 mg once daily for 21 days followed by 7 days off. BC: 600 mg of ribociclib once daily for 21 days followed by 7 days off and 2.5 mg of letrozole once daily continuously for a 28 day cycle. DTC: 24 mg orally once daily RCC: 18 mg orally once daily (use in combination with everolimus 5mg once daily) Metastatic CC*** Metastatic CC: 35 mg/m2 twice daily on day 1 through 5 and day 8 through 12 of a 28 day cycle. Maximum dose 80 mg twice daily. BRCA mutated advanced ovarian cancer*** GT OC: 400 mg orally twice daily until disease progression or unacceptable toxicity Lynparza (olaparib) tablets Lysodren (mitotane) Recurrent epithelial OC* Recurrent FTC* Recurrent PPC* BRCA mutated advanced ovarian cancer (OC)*** GT Deleterious or suspected deleterious germline BRCAmutated, HER-2-negative metastatic BC* GT Olaparib capsules are not interchangeable with olaparib tablets on a milligram-to-milligram basis OC, FTC, PPC, BC: 300 mg orally twice daily Olaparib capsules are not interchangeable with olaparib tablets on a milligram-to-milligram basis ACC ACC: 2-6 g/day in 3-4 divided doses titrated up to 9-10 g/day as tolerated. May be titrated higher as tolerated.

6 Self Administered Oncology Agents Page 6 of 19 Medication Indication Dosing HD Matulane (procarbazine) Mekinist (trametinib) Mektovi (binimetinib) Nerlynx (nertinib) Nexavar (sorafenib) Ninlaro (ixazomib) Odomzo (sonidegib) Pomalyst (pomalidomide) Revlimid (lenalidomide) Rubraca (rucaparib) Rydapt (midostaurin) Sprycel (dasatinib) Metastatic Melanoma GT with BRAF V600E or V600K mutations Metastatic NSCLC with BRAF V600E mutation GT In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDAapproved test Early stage HER2- overexpressed/amplified BC after trastuzumab RCC HCC DTC MM* Locally advanced BCC MM** MM* MDS MCL** OC with deleterious BRCA mutation GT, ** AML with FLT3 mutation GT, ASM SM-AHN Mast cell leukemia Adults with Ph+ CML, chronic phase Adults with Ph+ CML, chronic, accelerated, myeloid or lymphoid blast* Adults with Ph+ ALL Pediatric patients with Ph+ CML, chronic phase HD MOPP Regimen: 100 mg/m 2 daily for 14 days HD single agent adult: 2-4 mg/kg/day for 1 week, then 4-6mg/kg/day until max response/hematologic toxicity. At max response, maintain 1-2 mg/kg/day. Pediatric: 50 mg/m 2 /day for 1 week, then 100 mg/m 2 /day until max response/hematologic toxicity. At max response, maintain 50 mg/m 2 /day (suggested dose- dose should be individualized) Metastatic melanoma: 2 mg orally once daily as single agent (BRAF V600E positive) and in combination with dabrafenib (BRAF V600E or V600K positive) Metastatic NSCLC: 2 mg orally once daily in combination with dabrafenib Melanoma: 45 mg orally twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. If adverse reactions are unacceptable, reduce dose to 30 mg orally twice daily. Permanently discontinue if unable to tolerate Mektovi 30 mg orally twice daily. BC: 240 mg orally once daily continuously for one year HCC, RCC, DTC: 400 mg orally twice daily MM: 4 mg orally on Days 1, 8, and 15 of a 28-day cycle in combination with lenalidomide and dexamethasone BCC: 200 mg orally once daily MM: 4 mg once daily on days 1-21 of a repeated 28 day cycle. May be used as monotherapy or in combination with dexamethasone. MM, MCL: 25 mg once daily on days 1-21 of repeated 28 day cycles (MM - used in combination with dexamethasone) MDS: 10 mg once daily OC: 600 mg orally twice daily AML: 50 mg orally twice daily on day 8 to 21 of each cycle ASM, SM-AHN, Mast cell leukemia: 100 mg orally twice daily Adults Ph+ CML: 100 mg/day in chronic phase Adults Ph+ ALL, Ph+ CML accelerated, myeloid, or lymphoid blast phase: 140 mg once daily Pediatric Chronic phase CML: 40mg 140 mg once daily

7 Self Administered Oncology Agents Page 7 of 19 Medication Indication Dosing mcrc** GIST** HCC* Stivarga (regorafenib) Sutent (sunitinib) Sylatron (peginterferon alfa-2b) Tafinlar (dabrafenib) Tagrisso (osimertinib) Tarceva (erlotinib) Targretin a (bexarotene) Tasigna (nilotinib) RCC GIST* PNET GIST, mcrc, or HCC: 160 mg once daily for the first 21 days of a 28 day cycle. GIST or RCC: 50 mg/day; regimen should be 4 weeks on followed by 2 weeks off PNET: 37.5 mg/day continuously, no off period Melanoma Melanoma: 6 mcg/kg/week SC for 8 doses followed by 3 mcg/kg/week SC for up to 5 years Metastatic melanoma with BRAF V600E or V600K mutation GT Metastatic NSCLC with BRAF V600E mutation GT Metastatic NSCLC with EGFR T790M mutation*,gt NSCLC, first line for EGFR deletion of exon 19 or exon 21 substitutions GT NSCLC, maintenance or 2nd line treatment for EGFR deletion of exon 19 or exon 21 substitution GT * PC CTCL* Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia Ph+ CML chronic phase Adult patients with chronic phase and accelerated phase Ph+ CML resistant to, or intolerant to prior therapy that included imatinib Pediatric patients greater than or equal to 1 year of age with Ph+ CML chronic phase resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy Metastatic melanoma: 150 mg orally twice daily as a single agent (for BRAF V600E positive) or in combination with trametinib (for BRAF V600E or V600K positive) Metastatic NSCLC: 150 mg orally twice daily in combination with trametinib Metastatic NSCLC: 80 mg orally once daily NSCLC: 150 mg daily PC: 100 mg daily CTCL: 300 mg/m 2 /day Newly diagnosed Ph+CML: Adult: 300 mg twice daily Pediatric: 230mg/m 2 twice daily rounded to nearest 50 mg dose CML resistant or intolerant to imatinib: 400 mg twice daily CML resistant or intolerant to TKI therapy: 230 mg/m 2 rounded to nearest 50 mg dose

8 Self Administered Oncology Agents Page 8 of 19 Medication Indication Dosing GBM AA* Temodar a (temozolomide) Thalomid (thalidomide) MM ENL, acute treatment and maintenance therapy for prevention and suppression GBM: 75 mg/m 2 for 42 days with focal radiotherapy, then maintenance dose of 150 mg/m 2 once daily for days 1-5 of a 28 day cycle for cycle 1 then dose can be increased to 200 mg/m 2 for days 1-5 of a 28 day cycle based on toxicity, ANC, platelet count for a total of 6 cycles. AA: 150 mg/m 2 once daily for 5 consecutive days per 28- day cycle. Dose can be increased to 200 mg/m 2 /day for subsequent cycles based on toxicity, ANC, platelet count. MM: 200 mg once daily in 28 treatment cycles in combination with dexamethasone ENL: mg/day for an episode. Up to 400mg/day for severe cutaneous ENL Tretinoin, oral APL* APL: 45 mg/m 2 /day as two divided doses until 30 days after complete remission or 90 days total treatment, whichever occurs first Tykerb (lapatinib) HER2+Metastatic BC** HR+HER2+ Metastatic BC BC: 1,250 mg daily on days 1-21 of each cycle BC HER2+, HR+/HER2+: 1,500 mg once daily Venclexta (venetoclax) Verzenio (abemaciclib) Votrient (pazopanib) Xalkori (crizotinib) Xeloda a (capecitabine) Xtandi (enzalutamide) Yonsa (abiraterone acetate) Zejula (niraparib) Zelboraf (vemurafenib) Zolinza (vorinostat) Zydelig (idelalisib) Ω Zykadia (ceritinib) CLL with 17p deletion*,gt Advanced or metastatic, HR-positive, HER2-negative BC with disease progression following endocrine therapy RCC Soft tissue sarcoma* Metastatic ALK-positive NSCLC GT Metastatic ROS1-positive NSCLC Metastatic BC* CC, adjuvant and metastatic CRPC Metastatic castrate resistant prostate cancer (CRPC) Recurrent epithelial OC* Recurrent FTC* Recurrent PPC* Metastatic melanoma GT ECD with BRAF V600 mutation CTCL** Relapsed CLL in combination with rituximab Relapsed FL** Relapsed SLL** Metastatic ALK-positive NSCLC GT CLL: 20 mg once daily (QD) for 7 days on week 1, 50 mg QD for 7 days on week 2, 100 mg QD for 7 days on week 3, 200 mg QD for 7 days on week 4, 400 mg QD on week 5 and thereafter In combination with fulvestrant: 150mg twice daily Monotherapy: 200mg twice daily RCC, soft tissue sarcoma: 800 mg/day Metastatic NSCLC: 250 mg orally twice daily. BC, CC: 1,250 mg/m 2 twice daily for two weeks, then one week rest period, in 3-week cycles CRPC: 160 mg orally once daily CRPC: 500 mg orally once daily in combination with dexamethasone OC, FTC, PPC: 300 mg once daily Metastatic melanoma, ECD: 960 mg orally twice daily CTCL: 400 mg once daily CLL, FL, SLL: 150 mg orally twice daily NSCLC: 750 mg once daily

9 Self Administered Oncology Agents Page 9 of 19 Medication Indication Dosing CRPC Metastatic high-risk castration-sensitive prostate cancer (CSPC) Zytiga (abiraterone) CRPC: 1000 mg once daily (in combination with prednisone 5 mg twice daily) Reduce dose to 250 mg once daily in patients with baseline moderate hepatic impairment CSPC: 1000 mg orally once daily (in combination with prednisone 5mg once daily) AA-anaplastic astrocytoma, ACC-adrenal cortical carcinoma, ALL-acute lymphoblastic leukemia, AML- acute myeloid leukemia, APLacute promyelocytic, auto-hsct- autologous hematopoietic stem cell transplantation, leukemia, ASM-aggressive systemic mastocytosis, BC-breast cancer, BCC basal cell carcinoma, CC colorectal cancer, CEL-chronic eosinophilic leukemia, CLLchronic lymphocytic leukemia, CML-chronic myelogenous leukemia, CRPC-castration-resistant prostate cancer, CTCL- cutaneous T- cell lymphoma, DTC- differentiated thyroid carcinoma, DFSP-dermatofibrosarcoma protuberans, ECD erdheim-chester disease, ENL- Erythema nodosum leprosum, FL- B-cell non-hodgkin lymphoma, FTC- fallopian tube cancer, HER2- human epidermal growth factor receptor 2, HES-hyperosinophilic syndrome, HR+- hormone receptor positive, GBM- glioblastoma multiforme, GISTgastrointestinal stromal tumor, GVHD graft versus host disease, HCC-hepatocellular carcinoma, HL-Hodgkin s Disease,, MDS myelodysplastic syndrome, MDS/MPD-myelodysplastic/myeloproliferative disease, MM-multiple myeloma, MTC-medullary thyroid cancer, NET- neuroendocrine tumor, NSCLC-non small cell lung cancer, OC-ovarian cancer, PC-pancreatic cancer, PNET-pancreatic neuroendocrine tumors, PPC- primary peritoneal cancer, RCC-renal cell carcinoma, HR+BC-hormone receptor positive breast cancer, SCLC-small cell lung cancer, SEGA- subependymal giant cell astrocytoma, SLL- small lymphocytic lymphoma, SM-AHNsystemic mastocytosis with associated hematological neoplasm, TSC-tuberous sclerosis complex, mcrc metastatic colorectal cancer, MCL mantle cell lymphoma *Following one previous therapy based on FDA label **Following two previous therapies based on FDA label ***Following three previous therapies based on FDA label GT Genetic test with a companion diagnostic device required based on FDA label a generic available ^- for patient who have had an inadequate response to or are intolerant to hydroxyurea ~ Must be taken in combination with letrozole 2.5 mg once daily given continuously throughout the 28-day cycle for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC Use in combination with Zelboraf (vemurafenib) To be used in combination with fulvestrant: recommended dose is 500 mg administered on Days 1, 15, 29, and once monthly thereafter Ø Includes progressive, well-differentiated, non-functional tumors that are unresectable, locally advanced or metastatic to be used with 5 mg everolimus Ω Zydelig is not indicated and is not recommended for first-line treatment of any patient Use in patients for whom no other tyrosine kinase inhibitor is indicated Use in combination with standard cytarabine plus daunorubicin induction and cytarabine consolidation

10 Self Administered Oncology Agents Page 10 of 19 POLICY Prior Authorization Criteria for Approval A Target Agent will be approved when ALL of the following are met: 1. ONE of the following: A. There is documentation that the patient is currently receiving the target agent OR B. The prescriber states the patient is using the target agent AND is at risk if therapy is changed OR C. ALL of the following: i. ONE of the following: a. The patient has an FDA approved diagnosis for the target agent (evidence of a paid claim within the past 180 days, or patient is new to the claim system within the past 120 days and a statement by the physician that patient is currently taking the requested medication in the past 180 days) OR b. The use of the target agent is for an indication that is supported by compendia. (NCCN Compendium TM level of evidence 1 or 2A, AHFS (American Hospital Formulary Service), DrugDex level of evidence 1 or 2A AND ii. Genetic testing has been completed (if applicable) using an FDA approved genetic test if required for therapy with the target agent and results indicate therapy with target agent is appropriate AND iii. ONE of the following: a. The patient has tried and failed the first line agent for the intended indication (if applicable) OR b. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to the first line agent AND iv. ONE of the following: a. The requested agent is a preferred agent* (*preferred agents are determined by the client and may include both brand and generic agents) OR

11 Self Administered Oncology Agents Page 11 of 19 b. The requested agent is a non-preferred agent (as determined by the client) and the patient meets ONE of the following: 1) The patient s medication history indicates use of a preferred agent for the requested indication OR 2) The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent OR 3) The prescriber has provided documentation in support of use of the non-preferred agent over the preferred agent AND 2. The patient does not have an FDA labeled contraindication to the requested agent AND 3. The patient does not have an FDA labeled limitation of use for the requested agent that is otherwise not supported in National Comprehensive Cancer Network (NCCN) AND 4. ONE of the following: a. The dose is within FDA labeling OR b. The dose is not within FDA approved labeling and the prescriber has submitted documentation in support of therapy with a higher dose for the intended diagnosis Length of Approval: Up to 12 months FDA Approved Genetic Tests FDA Companion Diagnostics: RATIONALE For the purposes of the Self Administered Oncology Agents criteria, indications deemed appropriate are those approved in FDA labeling and/or supported by NCCN Drugs & Biologics compendia with a category 1 or 2A recommendation, AHFS, or Drugdex with level of evidence of 1 or IIa. Safety 1-51, Agent Afinitor / Afinitor Disperz (everolimus) Alecensa (alectinib) Alunbrig (brigatinib) Bosulif (bosutinib) Braftovi (encorafenib) Cabometyx (cabozantinib) Calquence (acalabrutinib) Contraindications Hypersensitivity to everolimus, to other rapamycin derivatives, or to any of the excipients Hypersensitivity to bosutinib

12 Self Administered Oncology Agents Page 12 of 19 Agent Caprelsa (vandetanib) Cometriq (cabozantinib) Cotellic (cobimetinib) Erleada (apalutamide) Erivedge (vismodegib) Farydak (panobinostat) Gilotrif (afatinib) Gleevec (imatinib) Hexalen (altretamine) Hycamtin (topotecan Ibrance (palbociclib) Iclusig (ponatinib) Idhifa (enasidenib) Imbruvica (ibrutinib) Inlyta (axitinib) Iressa (gefitinib) Jakafi (ruxolitinib) Kisqali (ribociclib) Kisqali Femara Pack (ribociclib and letrozole copackaged) Lenvima (lenvatinib) Lonsurf (trifluridine/tipiracil) Lynparza (olaparib) capsules Lynparza (olaparib) tablets Lysodren (mitotane) Matulane (procarbazine) Mekinist (trametinib) Mektovi (binimetinib) Nerlynx (nertinib) Nexavar (sorafenib) Ninlaro (ixazomib) Odomzo (sonidegib) Pomalyst (pomalidomide) Revlimid (lenalidomide) Rubraca (rucaparib) Rydapt (midostaurin) Sprycel (dasatinib) Stivarga (regorafenib) Sutent (sunitinib) Sylatron (peginterferon alfa- 2b) Tafinlar (dabrafenib) Tagrisso (osimertinib) Tarceva (erlotinib) Targretin (bexarotene) Contraindications Congenital long QT syndrome Pregnancy Hypersensitivity to altretamine, Bone marrow suppression, severe neurological toxicity Bone marrow suppression, hyper-sensitivity to topotecan or its ingredients Hypersensitivity to mitotane Bone marrow suppression, known hypersensitivity to procarbazine Known hypersensitivity to sorafenib or its components, use in combination with carboplatin and paclitaxel in patients with squamous cell lung cancer Pregnancy Pregnancy, hypersensitivity to lenalidomide Hypersensitivity to midostaurin or any of the excipients Autoimmune hepatitis, hepatic decompensation (Child-Pugh score >6, Blass B and C), hypersensitivity to peginterferon alfa-2a or peginterfon alfa-2b Pregnancy; known hypersensitivity to bexarotene or other components of the product

13 Self Administered Oncology Agents Page 13 of 19 Agent Tasigna (nilotinib) Temodar (temozolomide) Thalomid (thalidomide) Tretinoin (oral) Tykerb (lapatinib) Venclexta (venetoclax) Verzenio (abemaciclib) Votrient (pazopanib) Xalkori (crizotinib) Xeloda (capecitabine) Xtandi (enzalutamide) Yonsa (abiraterone acetate) Zejula (niraparib) Zelboraf (vemurafenib) Zolinza (vorinostat) Zydelig (idelalisib) Zykadia (ceritinib) Zytiga (abiraterone) Contraindications Hypokalemia, hypomagnesemia, QT prolongation Hypersensitivity to dacarbazine (DTIC) or Temodar component Pregnancy, thalidomide hypersensitivity Known hypersensitivity to tretinoin, any of its components, or, retinoid hypersensitivity Known hypersensitivity to lapatinib or Tykerb components Concomitant use with strong inhibitors of CYP3A at dose initiation and during dose ramp-up phase Severe renal failure, hypersensitivity to capecitabine or 5-fluorouracil Pregnancy Pregnancy History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis Women who are or may become pregnant REVISIONS Description section updated to include update to FDA Approved Indications chart. In Policy section: In Item 3 a i added Look-back period information. Moved the Kansas State Mandate information from being its own Item 4 to Item 3 a ii. Added in 3 c ii "The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to the first line agent" Updated Genetic Testing chart for required results. Rationale section updated to include updates to the Safety chart. In Coding section: HCPCS Code nomenclature correction: J8705 Added HCPCS code: J Added Zykadia (ceritinib) to the FDA Approved Indications chart Updated FDA Approved Indications chart for Imbruvica ((ibrutinib), Mekinist (trametinib), Nexavar (sorafenib), Revlimid (lenalidomide), Tykerb (lapatinib) In Policy section: Added Item 3 d The patient does not have any FDA labeled limitations of use Added to Length of Approval 1 month for dose titration requests Added to Length of Approval for all other requests to read 12 months for all other requests Added FDA Labeled Limitation of Use chart Updated Genetic Testing chart In Rationale section: Added Zykadia (ceritinib) to the Safety chart on Toxicities, Side Effects, Warnings, Precautions and Contraindications / Boxed Warnings

14 Self Administered Oncology Agents Page 14 of 19 REVISIONS Coding section reviewed Policy posted and effective Administrative Update Added Zydelig (idelalisib) to the FDA Approved Indications chart. Coding section removed as codes are not used for pharmacy benefit. Rationale section updated Policy published Policy effective Description updated to include: The addition of a list of the Target Drugs Updated the FDA Approved Indications chart including the addition of the following drugs; Afinitor Disperz, Farydak (panobinostat), Ibrance (palbociclib), Lenvima (lenvatinib), Lynparza (olaparib). In Policy section: In initial statement replaced "ONE" with "ALL" to read, "A Target Agent will be approved when ALL of the following are met:" Added "1. ONE of the following:" In 1 C b replaced the Kansas State mandate wording of "Meets the off-labeled use of an FDA approved prescription drug for cancer treatment 'if the prescription drug is recognized for treatment of the indication in one of the standard reference compendia or in substantially accepted peer reviewed medical literature. The prescribing physician shall submit to the insurer documentation supporting the proposed off-label use or uses if requested by the insurer.' (State mandate 40-2, 168 article 2 General Provisions) (History: L. 1999, ch. 128, 2; May 6.)" with "The use of the target agent is for an indication that is supported by compendia. (NCCN CompendiumTM level of evidence 1, 2A, or 2B, AHFS (American Hospital Formulary Service), DrugDex, Clinical Pharmacology) or the prescriber has submitted additional documentation supporting the requested therapeutic use" In 1 C removed "The patient does NOT have any FDA labeled contraindication(s)" as it is placed elsewhere in the policy language. In 2 removed "limitations of use" and added "contraindication" to read, The patient does not have an FDA labeled contraindication" Added 3 "The patient does not have an FDA labeled limitation of use that is otherwise not supported in National Comprehensive Cancer Network (NCCN)" In Length of Approval added "Up to" to read, "Up to 12 months for all other requests" Removed the "FDA Labeled Limitation of Use" chart Removed the "FDA Approved Genetic Test" chart, leaving the "FDA Approved Genetic Tests" link for more up to date reference Rationale section updated to include updating the Safety chart, In Revision section: Removed Revision information for , , Description section updated to include updates to the Target Drugs and FDA Approved Indications charts. Added: Iressa (gefitinib), Lonsurf (trifluridine/tipiracil), Odomzo (sonidegib) Removed: Oforta (fludarabine) In Policy section: In Item C added, "AND

15 Self Administered Oncology Agents Page 15 of 19 REVISIONS iv. If the requested agent is a non-preferred agent (as determined by the client) ONE of the following: a. The patient s medication history indicates use of a preferred agent for the requested indication OR b. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to the preferred agent OR c. The patient s genetic mutational status of the tumor supports use of the nonpreferred agent" In Item 3 add, "for the requested agent" to read, "The patient does not have an FDA labeled limitation of use for the requested agent that is otherwise not supported in National Comprehensive Cancer Network (NCCN)" In Length of Approval removed "1 month for dose titration requests", "Up to" and "for all other requests" to read "12 months" Rationale section Safety chart updated Published Retro-effective to The following target drugs were added to the Target Drugs, FDA Approved Indications, and Safety charts: "Cotellic TM (cobimetinib)", "Ninlaro (ixazomib)" and Tagrisso TM (osimertinib)" Published Retro-effective to The following target drug was added to the Target Drugs, FDA Approved Indications, and Safety charts: Alecensa (alectinib) Published June 8, Effective July 1, Description section updated: Added "Venclexta (venetoclax)" to Target Drugs Revised indication and/or dosing for Afinitor (everolimus), Gilotrif (afatinib), Ibrance (palbociclib), Iressa (gefitinib), and Xalkori (crizotinib) Rationale section updated Published August Effective July 1, Description section updated Added Cabometyx (cabozantinib) to the Target Drugs and FDA Approved Indications charts. On FDA Approved Indications chart: Updated indications for Gilotrif and Lenvima Updated references In Rationale section: Added Cabometyx (cabozantinib) to the Safety chart In the Description section: In the FDA Approved Indications chart added that "Zydelig is not indicated and is not recommended for first line treatment of any patient" Description section updated including FDA Approved Indications and Dosing chart update In Policy section: In Item 1 C iv added "ONE of the following: a. The requested agent is a preferred agent*(*preferred agents are determined by the client and may include both brand and generic agents)"

16 Self Administered Oncology Agents Page 16 of 19 REVISIONS In Item 1 C iv b added "and the patient meets" to read "The requested agent is a nonpreferred agent (as determined by the client), and the patient meets ONE of the following:" In Item 1 C iv b 3) removed "genetic mutational status of the tumor supports use of the non-preferred agent" and added "The prescriber has provided documentation in support of use of the non-preferred agent over the preferred agent" Added Item 4 "ONE of the following: a. The dose is within FDA labeling OR b. The dose is not within FDA approved labeling and the prescriber has submitted documentation in support of therapy with a higher dose for the intended diagnosis which has been reviewed and approved by the Clinical Review Pharmacist. In Length of Approval added "Up to" to read "Up to 12 months" Updated Rationale section Updated References Added Rubraca (rucaparib) to the Target Drugs and FDA Approved Indications charts. Updated FDA Approved Indications for Imbruvica (ibrutinib) and Tarceva (erlotinib). Rationale section updated In Revision section: Removed revision details for the following dates: , Policy published Policy retro-effective to Target Drugs and FDA Approved Indications charts updated to add Kisqali (ribociclib) Rationale section updated Policy published Policy retro-effective to In Description section Updated Target Drugs chart adding Zejula Updated FDA Approved Indications chart adding Zejula and updating Stivarga with a new indication Updated Rationale section Updated References Policy published Policy effective to In Description section Updated Target Drugs chart adding Alunbrig and Rydapt Updated FDA Approved Indications chart adding Alunbrig and Rydapt Updated Rationale section Updated References Policy published Policy retro-effective to Added to Target Drugs "Kisqali Femara Pack (ribociclib and letrozole co-packaged)". Added to FDA Approved Indications and Dosage chart information pertaining to Kisqali Femara Pack and updated Zykadia indications. Updated Rationale section Updated References Policy published Policy retro-effective to Updated FDA Approved Indications and Dosage chart adding new indications for Mekinist and Tafinlar

17 Self Administered Oncology Agents Page 17 of 19 REVISIONS To Target Drugs added to Target Drugs Idhifa (enasibenib) and Nerlynx (neratinib). Distinguished between Lynparza (olaparib) capsules and Lynparza (olaparib) tablets. To FDA Approved Indications and Dosage chart added information pertaining to Idhifa and Nerlynx. Distinguished between Lynparza (olaparib) capsules and Lynparza (olaparib) tablets. Updated the indication for Imbruvica. Updated Rationale section Updated References Policy published Policy retro-effective to To Target Drugs and FDA Approved Indications added Verzenio (abemaciclib) In Rationale section: To Safety chart added Verzenio (abemaciclib) Policy published Policy retro-effective to Added Calquence (acalabrutinib) as a target drug In FDA Approved Indications chart added Calquence (acalabrutinib) and updated Zelboraf indications Rationale section updated Policy correction posted adding the revision into the Revision section, which had not been added at the original publication on Policy posted Policy retro-effective to In FDA Approved Indications chart updated Sprycel indications Description section updated with updates to the FDA Approved Indications chart In Policy section: Removed "or 2B" and "Clinical Pharmacology) or the prescriber has submitted additional documentation supporting the requested therapeutic use" and added "level of evidence 1 or 2A" to read "The use of the target agent is for an indication that is supported by compendia. (NCCN Compendium TM level of evidence 1 or 2A, AHFS (American Hospital Formulary Service), DrugDex level of evidence 1 or 2A)" Rationale section updated In FDA Approved Indications chart updated indication for Cabometyx and Gilotrif; added new indication for Lynparza tabs; and updated chart key Policy posted Policy retro-effective to In FDA Approved Indications chart added Erleada (apalutamide) and updated Zytiga indications Updated Rationale section Updated References Policy posted Policy retro-effective to Imbruvica 70mg capsules, 140 mg tablet, 280 mg tablet, 420 mg tablet, 560 mg tablet now available. (The policy does not reflect dosages, so no policy document updates were made.) Policy posted Policy retro-effective to

18 Self Administered Oncology Agents Page 18 of 19 REVISIONS Updated the FDA Indications and Dosage chart to add Tasigna 50mg dosage and new pediatric indication Policy posted Policy retro-effective to In FDA Indications and Dosage chart added the new drug Yonsa (abiraterone acetate). Rationale section updated Policy posted Policy retro-effective to In FDA Indications and Dosage chart added the new drugs Braftovi (encorafenib) and Mektovi (binimetinib). Rationale section updated REFERENCES 1. Afinitor/Afinitor Disperz prescribing information. Novartis. June Bosulif prescribing information. Pfizer. April Caprelsa prescribing information. AstraZeneca Pharmaceuticals. July Cometriq prescribing information. Exelixis, Inc. May Cotellic prescribing information. Genentech. May Erivedge prescribing information. Genentech. May Farydak prescribing information. Novartis. June Gilotrif prescribing information. Boehringer Ingelheim Pharmaceuticals. January Gleevec prescribing information. Novartis. January Hexalen Prescribing Information. MGI PHARMA, INC. May Hycamtin Prescribing Information. GSK. June Ibrance prescribing information. Pfizer. February Iclusig prescribing Information. ARIAD Pharmaceuticals. June Imbruvica prescribing information. Pharmacyclics, Inc. August Inlyta prescribing information. Pfizer. New York, NY. August Iressa prescribing information. AstraZeneca. July Jakafi prescribing information. Incyte. March Deleted 19. Lenvima prescribing information. Eisai. May Lonsurf prescribing information. Taiho Oncology. September Lynparza capsules prescribing information. AstraZeneca. August Lysodren Prescribing Information. E.R. Squibb & Sons, L.L.D. March Matulane Prescribing Information. Sigma-tau. December Mekinist Prescribing information. GlaxoSmithKline. November Nexavar prescribing information. Bayer. July Odomzo prescribing information. Novartis. May Deleted 28. Pomalyst prescribing information. Celgene Corporation. June Revlimid prescribing information. Celgene Corporation. February Sprycel prescribing information. E.R. Squibb & Sons, L.L.C. November Stivarga prescribing information. Bayer Healthcare Pharmaceuticals. April Sutent prescribing information. Pfizer. December Sylatron prescribing information. Schering Corporation. May Tafinlar prescribing information. GlaxoSmithKline. January Tagrisso prescribing information. AstraZeneca. November 2015.

19 Self Administered Oncology Agents Page 19 of Tarceva prescribing information. Genentech. October Targretin prescribing information. Valeant. February Tasigna prescribing information. Novartis. January Temodar Prescribing Information. Merck Sharp & Dohme Corp. September Thalomid prescribing information. Celgene Corporation. June Tretinoin prescribing information. Barr Laboratories, Inc. May Tykerb prescribing information. GSK. December Votrient prescribing information. GSK. April Xalkori prescribing information. Pfizer March Xeloda prescribing information. Genentech, Inc. February Xtandi prescribing information. Astellas Pharma US, Inc. September Zelboraf prescribing information. Genentech, USA. November Zolinza prescribing information. Merck, Sharp & Dohme Corp. December Zydelig prescribing information. Gilead Sciences, Inc. July Zykadia prescribing information. Novartis Pharmaceuticals. February Zytiga prescribing information. Janssen Biotech, Inc. May Verbraecken J et al. Body surface area in normal-weight, overweight, and obese adults. A Comparison study. Metabolism Clinical and Experimental 2006;55: Sacco Jj, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: A multicentre retrospective study. PLoS ONE 5(1):e8933. Doi: /journal.pone Ninlaro prescribing information. Millenium. November Alecensa prescribing information. Genentech. December Venclexta prescribing information. AbbVie Inc. April Cabometyx prescribing information. Exelixis Inc. December Rubraca prescribing information. Clovis Oncology. December Kisqali prescribing information. Novartis. March Zejula prescribing information. Tesaro. March Rydapt prescribing information. Norvatis. April Alunbrig prescribing information. Ariad. April Kisqali Femara Pack prescribing information. Novartis. May Nerlynx prescribing information. Puma Biotech. July Idhifa prescribing information. Celgene. August Lynparza tablets prescribing information. AstraZeneca. January Verzenio prescribing information. Eli Lilly and Company. September Calquence prescribing information. AstraZeneca. November Erleada prescribing information. Janssen Ortho LLC. February Yonsa prescribing information. Sun Pharmaceuticals Inc. May Braftovi prescribing information. Array BioPharma Inc. June Mektovi prescribing information. Array BioPharma Inc. June Kansas Statute 40-2, Accessed

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Self Administered Oncology Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Self Administered Oncology Agents Prime Therapeutics will review Prior

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

ORAL ONCOLOGY CRITERIA

ORAL ONCOLOGY CRITERIA ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year

ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)

More information

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications

Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

Clinical Therapeutic Intelligence Report: Year in Review

Clinical Therapeutic Intelligence Report: Year in Review Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted

More information

Pharmacy Policy Bulletin

Pharmacy Policy Bulletin Pharmacy Policy Bulletin Title: Policy #: Oncology Agents Rx.01.67 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some

More information

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607)

Overview of Cancer. Laura Bingell RN Transition Center Nurse for MFP (607) Overview of Cancer Laura Bingell RN Transition Center Nurse for MFP (607)962-8225 lbingell@ilny.org What is Cancer? A collection of related diseases in which some of the body s cells begin to divide abnormally

More information

Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)

More information

Sutent. Sutent (sunitinib) Description

Sutent. Sutent (sunitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 5 Last Review Date: September 15, 2017 Sutent Description Sutent (sunitinib)

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Oncology Clinical Review Prior Authorization (Oncology-CRPA) Rx Drugs POLICY NUMBER: Pharmacy-33 EFFECTIVE DATE: 10/13 LAST REVIEW DATE: 09/05/2018 If the member s subscriber contract excludes

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Oncology Clinical Review Prior Authorization (Oncology-CRPA) Rx Drugs POLICY NUMBER: Pharmacy-33 EFFECTIVE DATE: 10/13 LAST REVIEW DATE: 03/22/2018 If the member s subscriber contract excludes

More information

Tasigna. Tasigna (nilotinib) Description

Tasigna. Tasigna (nilotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Oncology Clinical Review Prior Authorization (Oncology-CRPA) Rx Drugs POLICY NUMBER: Pharmacy-33 EFFECTIVE DATE: 10/13 LAST REVIEW DATE: 11/12/2018 If the member s subscriber contract excludes

More information

Nexavar. Nexavar (sorafenib) Description

Nexavar. Nexavar (sorafenib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.60 Section: Prescription Drugs Effective Date: July 1,2017 Subject: Nexavar Page: 1 of 5 Last Review

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Sutent. Sutent (sunitinib) Description

Sutent. Sutent (sunitinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)

More information

Bosulif. Bosulif (bosutinib) Description

Bosulif. Bosulif (bosutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: CP.PHAR.63 Effective Date: 06.01.11 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Pazopanib (Votrient) Reference Number: CP.PHAR.81 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end

More information

Clinical Policy: Lenvatinib (Lenvima) Reference Number: CP.CPA.251 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Lenvatinib (Lenvima) Reference Number: CP.CPA.251 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Lenvima) Reference Number: CP.CPA.251 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Tasigna) Reference Number: CP.CPA.162 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Oral Chemotherapy Agents

Oral Chemotherapy Agents Oral Chemotherapy Agents NEW ADVANCES IN TARGETED THERAPY, OVERCOMING BARRIERS AND PROMOTING ADHERENCE KATIE SIAS, PHARMD CLINICAL PHARMACY COORDINATOR HEMATOLOGY/ONCOLOGY MIDMICHIGAN MEDICAL CENTER -

More information

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School

Genetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW

More information

Clinical Policy: Pazopanib (Votrient) Reference Number: ERX.SPA.139 Effective Date:

Clinical Policy: Pazopanib (Votrient) Reference Number: ERX.SPA.139 Effective Date: Clinical Policy: (Votrient) Reference Number: ERX.SPA.139 Effective Date: 03.01.14 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Cancer Therapy Update in 2017

Cancer Therapy Update in 2017 Cancer Therapy Update in 2017 Editor: Le Wang, M.D., Ph.D Medical Oncology and Hematology (Board-Certified) Ibrutinib (Imbruvica) Pharmacyclics 1 /19/2017 Lymphoma Marginal Zone Lymphoma (MZL), Relapsed/Refractory

More information

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and

More information

Votrient. Votrient (pazopanib) Description

Votrient. Votrient (pazopanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.83 Subject: Votrient Page: 1 of 6 Last Review Date: June 22, 2018 Votrient Description Votrient (pazopanib)

More information

Clinical Policy: Imatinib (Gleevec) Reference Number: CP.PHAR.65 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Clinical Policy: Imatinib (Gleevec) Reference Number: CP.PHAR.65 Effective Date: Last Review Date: Line of Business: Oregon Health Plan Clinical Policy: (Gleevec) Reference Number: CP.PHAR.65 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Gleevec. Gleevec (imatinib) Description

Gleevec. Gleevec (imatinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1113-6 Program Prior Authorization/Notification Medication Votrient TM (pazopanib) P&T Approval Date 1/12/2010, 9/2010, 12/2010,

More information

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards

Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,

More information

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,

More information

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description

Afinitor. Afinitor and Afinitor Disperz (everolimus) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

Votrient. Votrient (pazopanib) Description

Votrient. Votrient (pazopanib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.83 Subject: Votrient Page: 1 of 6 Last Review Date: December 2, 2016 Votrient Description Votrient

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tagrisso) Reference Number: CP.PHAR.294 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1037-6 Program Prior Authorization/Notification Medication Gleevec (imatinib mesylate) P&T Approval Date 8/2008, 6/2009, 6/2010,

More information

Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing

Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing Oral Oncology/Hematology Reference Indications & Common Dosing Name FDA Indication Compendia Approved Uses Adult Dosing ABIRATERONE Prostate CA: castrate Prostate CA: castrate resistant metastatic dz Prostate

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Sprycel) Reference Number: CP.PHAR.72 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management

More information

Tarceva. Tarceva (erlotinib) Description

Tarceva. Tarceva (erlotinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)

More information

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC) CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63

Clinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Effective Date: 01/18 Last Review Date: Coding Implications Revision Log Description The intent of the criteria is to ensure

More information

I. Diagnosis of the cancer type in CUP

I. Diagnosis of the cancer type in CUP Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Gilotrif. Gilotrif (afatinib) Description

Gilotrif. Gilotrif (afatinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 6 Last Review Date: March 16, 2018 Gilotrif Description Gilotrif (afatinib)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Sutent) Reference Number: CP.PHAR.73 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased

2. Treatment of patients with metastatic, squamous NSCLC progressing after platinumbased Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.39 Subject: Gilotrif Page: 1 of 5 Last Review Date: September 15, 2017 Gilotrif Description Gilotrif

More information

NEXAVAR (sorafenib tosylate) oral tablet

NEXAVAR (sorafenib tosylate) oral tablet NEXAVAR (sorafenib tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage

Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 5 Last Review Date: March 16, 2018 Lynparza Description Lynparza (olaparib)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Venclexta) Reference Number: CP.PHAR.129 Effective Date: 07.17.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy

Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy Safe Practices in Oral Anticancer Medications: Implications for Community Pharmacy Faculty Disclosures Dr. Holle has provided content expertise on patient education materials for Innocrin Pharmaceuticals

More information

Clinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan

Clinical Policy: Erlotinib (Tarceva) Reference Number: CP.PHAR74 Effective Date: Last Review Date: Line of Business: Oregon Health Plan Clinical Policy: (Tarceva) Reference Number: CP.PHAR74 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy

More information

Clinical Therapeutic Intelligence Report: 2015 Year in Review

Clinical Therapeutic Intelligence Report: 2015 Year in Review Clinical Therapeutic Intelligence Report: 2015 Year in Review This issue highlights the many ground-breaking therapies approved by the U.S. Food and Drug Administration over the course of 2015. Highlights

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Brigatinib (Alunbrig) Reference Number: CP.PHAR.342 Effective Date: 07.17.17 Last Review Date: 05.18 Line of Business: Commercial; Medicaid Revision Log See Important Reminder at the end

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 09.26.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Tisagenlecleucel (Kymriah) Reference Number: CP.PHAR.361 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at

More information

Opdivo. Opdivo (nivolumab) Description

Opdivo. Opdivo (nivolumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Venclexta) Reference Number: CP.PHAR.129 Effective Date: 07.17.18 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Erbitux) Reference Number: CP.PHAR.317 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC

OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT. Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC OPENING KEYNOTE: PRECISION MEDICINE AT THE INFLECTION POINT Session PM1, March 5, 2018 Damon Hostin, CEO, Precision Medicine Alliance, LLC 1 Conflicts of Interest Damon Hostin Has no real or apparent conflicts

More information

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded

Azacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Sutent) Reference Number: ERX.SPA.77 Effective Date: 03.01.14 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

LYNPARZA (olaparib) oral capsule and tablet

LYNPARZA (olaparib) oral capsule and tablet LYNPARZA (olaparib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

CABOMETYX (cabozantinib) oral tablet

CABOMETYX (cabozantinib) oral tablet CABOMETYX (cabozantinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:

Clinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date: Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Lynparza. Lynparza (olaparib) Description

Lynparza. Lynparza (olaparib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.52 Subject: Lynparza Page: 1 of 4 Last Review Date: September 15, 2017 Lynparza Description Lynparza

More information

Keytruda. Keytruda (pembrolizumab) Description

Keytruda. Keytruda (pembrolizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Stivarga) Reference Number: CP.CPA.157 Effective Date: 11.16.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Imbruvica) Reference Number: HIM.PA.SP48 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1101-7 Program Prior Authorization/Notification Medication Sutent (sunitinib malate) P&T Approval Date 8/2008, 6/2009, 6/2010,

More information

Subject: Axitinib (Inlyta ) Tablets

Subject: Axitinib (Inlyta ) Tablets 09-J1000-67 Original Effective Date: 05/15/12 Reviewed: 12/12/18 Revised: 01/15/19 Subject: Axitinib (Inlyta ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018

Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Compassionate use programma's die zijn goedgekeurd door het CBG Laatst bijgewerkt op: 21 juni 2018 Het CBG kan in schrijnende gevallen toestemming verlenen voor het in de handel brengen van een geneesmiddel

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17 Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

IMBRUVICA (ibrutinib) oral capsule and tablet

IMBRUVICA (ibrutinib) oral capsule and tablet IMBRUVICA (ibrutinib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

Avastin. Avastin (bevacizumab) Description

Avastin. Avastin (bevacizumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Mekinist) Reference Number: CP.PHAR.240 Effective Date: 07.01.16 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of

More information

Subject: Dasatinib (Sprycel ) Tablets

Subject: Dasatinib (Sprycel ) Tablets 09-J1000-43 Original Effective Date: 01/01/12 Reviewed: 01/10/18 Revised: 02/15/18 Subject: Dasatinib (Sprycel ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date:

Clinical Policy: Cetuximab (Erbitux) Reference Number: ERX.SPA.261 Effective Date: Clinical Policy: (Erbitux) Reference Number: ERX.SPA.261 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information